Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 11/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GCK | P35557 | 3/20 | 0.47 |
| ▸ | GCKR | Q14397 | 2/20 | 0.47 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.46 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.46 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.46 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3556996 | 0.83 | LMNA (0.68) | HSD11B1GAALMNAGCKGCKR | |
| SCHEMBL3551978 | 0.83 | LMNA (0.68) | HSD11B1GAALMNAGCKGCKR | |
| SCHEMBL3555800 | 0.83 | LMNA (0.68) | HSD11B1GAALMNAGCKGCKR | |
| SCHEMBL13036466 | 0.80 | HSD11B1 (0.58) | HSD11B1GAALMNACYP2C19 | |
| SCHEMBL11959899 | 0.80 | HSD11B1 (0.58) | HSD11B1GAALMNACYP2C19 | |
| SCHEMBL11959897 | 0.79 | HSD11B1 (0.54) | HSD11B1GAACYP3A4KCNH2GCK | |
| SCHEMBL13036477 | 0.78 | HSD11B1 (0.53) | HSD11B1GAACYP3A4KCNH2GCK | |
| SCHEMBL752401 | 0.75 | CNR1 (0.62) | HSD11B1GCKGCKR | |
| SCHEMBL3550207 | 0.74 | HSD11B1 (0.71) | HSD11B1POLBCYP3A4KCNH2 | |
| SCHEMBL13036461 | 0.74 | HSD11B1 (0.71) | HSD11B1POLBCYP3A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1753421-B1 | ARYLSULFONAMIDES AND USES AS HYDROXYSTEROID DEHYDROGENASE | AMGEN INC (US) | 2012-08-01 | — | — | EP | claimed |
| EP-2243494-A1 | Pharmaceutical composition, comprising a steroid-dehydrogenase-reductase inhibitor, and a mineralocorticoid receptor antagonist. | OntoChem GmbH (DE) | 2010-10-27 | — | — | EP | claimed |
| US-20090075975-A1 | ARYLSULFONAMIDES AND USES RELATED THERETO | AMGEN INC. | 2009-03-19 | — | — | US | claimed |
| US-7495012-B2 | Arylsulfonamides and uses related thereto | AMGEN INC. (US) | 2009-02-24 | — | — | US | claimed |
| EP-1753421-A2 | ARYLSULFONAMIDES AND USES AS HYDROXYSTEROID DEHYDROGENASE | Amgen Inc. (US) | 2007-02-21 | — | — | EP | claimed |
| US-20050288271-A1 | Arylsulfonamides and uses related thereto | AMGEN INC. (US) | 2005-12-29 | — | — | US | claimed |
| WO-2005118538-A2 | ARYLSULFONAMIDES AND USES AS HYDROXYSTEROID DEHYDROGENASE | AMGEN, INC. (US) | 2005-12-15 | — | — | WO | claimed |
| US-20170234881-A1 | METHODS OF DIAGNOSING AND TREATING CANCER | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2017-08-17 | — | — | US | disclosed |
| EP-3194615-A1 | METHODS OF DIAGNOSING AND TREATING CANCER | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-07-26 | — | — | EP | disclosed |
| WO-2016034742-A1 | METHODS OF DIAGNOSING AND TREATING CANCER | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2016-03-10 | — | — | WO | disclosed |
| EP-1753421-B1 | ARYLSULFONAMIDES AND USES AS HYDROXYSTEROID DEHYDROGENASE | AMGEN INC (US) | 2012-08-01 | — | — | EP | disclosed |
| EP-1753421-B1 | ARYLSULFONAMIDES AND USES AS HYDROXYSTEROID DEHYDROGENASE | AMGEN INC (US) | 2012-08-01 | — | — | EP | disclosed |
| US-7834047-B2 | Arylsulfonamides and uses related thereto | AMGEN INC. (US) | 2010-11-16 | — | — | US | disclosed |
| US-20090075975-A1 | ARYLSULFONAMIDES AND USES RELATED THERETO | AMGEN INC. | 2009-03-19 | — | — | US | disclosed |
| US-7495012-B2 | Arylsulfonamides and uses related thereto | AMGEN INC. (US) | 2009-02-24 | — | — | US | disclosed |
| US-7495012-B2 | Arylsulfonamides and uses related thereto | AMGEN INC. (US) | 2009-02-24 | — | — | US | disclosed |
| US-7495012-B2 | Arylsulfonamides and uses related thereto | AMGEN INC. (US) | 2009-02-24 | — | — | US | disclosed |
| EP-1753421-A2 | ARYLSULFONAMIDES AND USES AS HYDROXYSTEROID DEHYDROGENASE | Amgen Inc. (US) | 2007-02-21 | — | — | EP | disclosed |
| US-20050288271-A1 | Arylsulfonamides and uses related thereto | AMGEN INC. (US) | 2005-12-29 | — | — | US | disclosed |
| WO-2005118538-A2 | ARYLSULFONAMIDES AND USES AS HYDROXYSTEROID DEHYDROGENASE | AMGEN, INC. (US) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075975-A1 | ARYLSULFONAMIDES AND USES RELATED THERETO | ARSA, STS, SULT2A1 | HSD11B1 162/4885GAA 108/4885POLB 3093/4885 |
| US-20050288271-A1 | Arylsulfonamides and uses related thereto | ARSA, STS, SULT2A1 | HSD11B1 162/4885GAA 108/4885POLB 3093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.